Free tool
FAERS Monitor: Azulfidine En-Tabs
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021243 or its brand name (Azulfidine En-Tabs, Sulfasalazine). Reports on generic versions are filed under their own applications.
Reports
78,454
Serious
65,745
84% of reports
Hospitalization
21,747
Death reported
7,496
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective29,490
- rheumatoid arthritis19,666
- pain16,091
- drug intolerance13,852
- arthralgia13,600
- fatigue13,447
- joint swelling12,846
- off label use11,276
- rash11,118
- abdominal discomfort10,166
- contraindicated product administered9,780
- condition aggravated9,702
- alopecia9,553
- synovitis9,347
- arthropathy9,286
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 636 |
| 2005 | 614 |
| 2006 | 684 |
| 2007 | 832 |
| 2008 | 843 |
| 2009 | 829 |
| 2010 | 870 |
| 2011 | 1,147 |
| 2012 | 1,441 |
| 2013 | 1,324 |
| 2014 | 1,510 |
| 2015 | 2,401 |
| 2016 | 3,318 |
| 2017 | 5,227 |
| 2018 | 6,253 |
| 2019 | 7,389 |
| 2020 | 11,228 |
| 2021 | 7,186 |
| 2022 | 7,151 |
| 2023 | 5,138 |
| 2024 | 5,753 |
| 2025 | 4,579 |
| 2026 | 2,100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,975,705 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 9,347 | 287.1 | 279.1 | 1,286,069 |
| contraindicated product administeredSignal | 9,780 | 127.4 | 124.5 | 831,681 |
| rheumatoid arthritisSignal | 19,666 | 55.9 | 55.2 | 882,360 |
| arthropathySignal | 9,286 | 53.6 | 52.4 | 400,002 |
| drug intoleranceSignal | 13,852 | 44.7 | 44.0 | 509,350 |
| joint swellingSignal | 12,846 | 31.8 | 31.3 | 344,486 |
| abdominal discomfortSignal | 10,166 | 17.2 | 16.9 | 147,163 |
| alopeciaSignal | 9,553 | 13.7 | 13.4 | 107,599 |
| arthralgiaSignal | 13,600 | 9.0 | 8.9 | 95,848 |
| condition aggravatedSignal | 9,702 | 8.8 | 8.6 | 65,918 |
| painSignal | 16,091 | 7.2 | 7.1 | 85,926 |
| rashSignal | 11,118 | 7.0 | 6.9 | 56,792 |
| drug ineffectiveSignal | 29,490 | 6.1 | 6.1 | 131,540 |
| fatigueSignal | 13,447 | 4.7 | 4.6 | 39,892 |
| off label useSignal | 11,276 | 3.5 | 3.4 | 20,570 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.